Histrelin clinical trials
Also written Vantas.
How each study uses histrelin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 24 Dec 1991 · SUPPRELIN · NDA 019836 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2000 (2)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2004 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Endo Pharmaceuticals (3) · NRG Oncology (1)
Often tested with
Tested in the same studies.
Bicalutamide (1) · Buserelin (1) · Darolutamide (1) · Degarelix (1) · Flutamide (1) · Goserelin (1) · Leuprolide (1) · Relugolix (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test histrelin, phase 3 first.
Studies
Open first, then newest update. How each study uses histrelin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialActive, not recruitingPhase 3NRG OncologyNCT05050084Written as HistrelinHow we know
- Study of Histrelin Subdermal Implant in Patients With Prostate CancerCompletedPhase 3Endo PharmaceuticalsNCT01394263Written as Histrelin hydrogel implantHow we know
- Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate CancerCompletedPhase 3Endo PharmaceuticalsNCT01697384Written as histrelin acetateHow we know
- Histrelin Subcutaneous Implant in Children With Central Precocious PubertyCompletedPhase 3Endo PharmaceuticalsNCT00779103Written as Histrelin Subcutaneous ImplantHow we know
Given beside what is tested · 3 — histrelin is usual care or a partner of the new treatment
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT03678025Written as Histrelin AcetateHow we know
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerActive, not recruitingPhase 2/3VA Office of Research and DevelopmentNCT04787744Written as Goserelin, Histrelin, Leuprolide & TriptorelinHow we know
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialActive, not recruitingPhase 3NRG OncologyNCT04513717Written as HistrelinHow we know
As the comparator · 2 — what is tested is compared with histrelin
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRecruitingPhase 2Mayo ClinicNCT06378866Written as HistrelinHow we know
- Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate CancerCompletedPhase 2University of Colorado, DenverNCT02278185Written as histrelin acetateHow we know
Codes
What other systems call histrelin · ClinicalTrials.gg INT002888
- MeSH (NLM) C029256histrelinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) H50H3S3W74HISTRELINConfirmed FDA, NLM, Wikidata
- RxNorm 50975Confirmed FDA, Wikidata
- Wikidata Q5871149histrelinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74270HistrelinOne source FDA
- DrugBank DB06788One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C029256 | histrelin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | H50H3S3W74 | HISTRELIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 50975 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5871149 | histrelin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74270 | Histrelin | One source FDA |
| DrugBank | DB06788 | — | One source Wikidata |
Also registered as histrelin acetate (UNII QMG7HLD1ZE · RxNorm 1294622).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.